NR4A1 and neoplasm: In the overall cohort of patients that were treated with trastuzumab in the neoadjuvant setting (n = 887), patients with pCR had a significantly better EFS outcome than patients with residual disease in a multivariable model stratified by clinical trial and adjusted by treatment arm, hormone receptor status, tumor size, and node status (aHR for pCR vs residual disease: 0.47; 95% CI, 0.34-0.66; P < .001).